Giulio Metro
机构: Medical Oncology, Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Italy
每年引用次数
引用次数
引用: 5,587
H-指数: 42
I10-指数 : 126
出版物: 312
Advances on EGFR mutation for lung cancer
Giulio Metro , Lucio Crinò
Translational lung cancer research 1 ( 1) 5 -13
55
2012
Perspectives on salvage therapy for non-small-cell lung cancer.
Giulio Metro , Lucio Crinò , Federico Cappuzzo , Luca Toschi
Oncology 19 ( 8) 989 -995
8
2005
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?
Giulio Metro , Lucio Crinò , Vincenzo Minotti
Journal of Thoracic Disease 4 ( 6) 635 -638
6
2012
Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis.
Giulio Metro , Alessandra Fabi , Giorgio Sacerdoti , Simona Pino
Anticancer Research 27 ( 2) 1167 -1169
10
2007
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Giulio Metro , Francesco Cognetti , Antonello Vidiri , Michelangelo Russillo
Anticancer Research 29 ( 7) 2607 -2610
28
2009
Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.
Paola Papaldo , Giulio Metro , Francesco Cognetti , Carmen Nuzzo
Anticancer Research 28 1245 -1258
12
2008
Sacrum colon-rectal cancer metastasis: microwave ablation for palliative pain treatment.
Luigina Graziosi , Daniele Maiettini , Stefania Rebonato , Alberto Rebonato
Recenti progressi in medicina 107 ( 12) 673 -676
2016
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
Alain Gelibter , Diego L. Cortinovis , Matteo Santoni , Marco Russano
Thoracic Cancer 12 ( 6) 880 -889
25
2021
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
Giulio Metro , Guido Bellezza , Sara Baglivo , Maria Laura Belladonna
Genes 12 ( 2) 273
2021
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma
Giulio Metro , Chenglin Guo , Lunxu Liu , Jiandong Mei
Translational lung cancer research 10 ( 2) 965 -980
2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Marcello Tiseo , David J. Pinato , Giulio Metro , Sergio Bracarda
European Journal of Cancer 148 24 -35
1
2021
Supportive Care: Low Cost, High Value.
Giulio Metro , Maryam Lustberg , Fausto Roila , Jann Arends
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 41 ( 41) 1 -11
2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
David J Pinato , David J Pinato , Antonino Grassadonia , Giulio Metro
Journal for ImmunoTherapy of Cancer 9 ( 4)
2
2021
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.
Giulio Metro , Alessandro Inno , Nicola Maurea , Stefania Gori
Cancer Immunology, Immunotherapy 1 -13
2021
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
Giulio Metro , Guido Bellezza , Sara Baglivo , Francesca Romana Tofanetti
Genes 12 ( 5) 679
2021
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
Marcello Tiseo , David J. Pinato , David J. Pinato , Giulio Metro
European Journal of Cancer 150 224 -231
2021
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Giulio Metro , Guido Bellezza , Giulio Cerea , Laura Giannetta
Human Vaccines & Immunotherapeutics 1 -9
2021
Programmed cell death ligand 1(PD-L1), Programmed death 1+(PD-1) lymphocytes and Tumor infiltrating lymphocytes (TILs): are they playing a role in predicting response to anti-PD-1 therapies?
Chiara Bennati , Giulia Leonardi , Angelo Sidoni , Alessio Gili
Journal of Clinical Oncology 34
2016
Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Paola Bordi , Lorenzo Antonuzzo , Simona Scodes , Lorenza Landi
medRxiv
2020
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Giulio Metro , Lucio Crinò
Expert Review of Anticancer Therapy 11 ( 5) 673 -682
34
2011